The combination of Cmp3—a highly selective pharmacologic inhibitor of NR5A2—with standard-of-care chemotherapy exhibited robust synergistic antitumor efficacy, resulting in enhanced CSC depletion, durable tumor regression, and prolonged survival in preclinical CRC models. The gene discussed is NR5A2; the disease is neoplasm.